ValiRx’s (VAL) “Speculative Buy” Rating Reiterated at Beaufort Securities

ValiRx (LON:VAL)‘s stock had its “speculative buy” rating reiterated by stock analysts at Beaufort Securities in a research report issued on Friday.

Shares of ValiRx (VAL) traded up GBX 0.05 ($0.00) during midday trading on Friday, hitting GBX 4.88 ($0.07). The stock had a trading volume of 6,752,599 shares, compared to its average volume of 28,510,000. The firm has a market capitalization of $12.78 and a P/E ratio of -81.25. ValiRx has a fifty-two week low of GBX 0.90 ($0.01) and a fifty-two week high of GBX 7.75 ($0.11).

COPYRIGHT VIOLATION WARNING: “ValiRx’s (VAL) “Speculative Buy” Rating Reiterated at Beaufort Securities” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/14/valirxs-val-speculative-buy-rating-reiterated-at-beaufort-securities.html.

ValiRx Company Profile

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply